Samatasvir

Structural formula
General
Surname	Samatasvir
other names	IDX-719; N - [(1 R ) -2 - [(2 S ) -2- [6- [2- [4- [2 - [(2 S ) -1 - [(2 S ) -2- (methoxycarbonylamino) - 3-methylbutanoyl] pyrrolidin-2-yl] -1 H -imidazol-5-yl] phenyl] thieno [3,2- b ] thiophen-5-yl] -1 H -benzimidazol-2-yl] pyrrolidin-1- yl] -2-oxo-1-phenylethyl] carbamic acid methyl ester ( IUPAC );
Molecular formula	C 47 H 48 N 8 O 6 S 2
External identifiers / databases
PubChem	53302707
Wikidata	Q21098899
properties
Molar mass	885.062 g mol −1
safety instructions
GHS hazard labeling ; no classification available
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Samatasvir is an experimental drug and antiviral used to treat infections with the hepatitis C virus . This was originally developed by Idenix and now by MSD .

properties

Samatasvir belongs to the group of NS5A inhibitors . It binds to the non-structural protein 5A of the hepatitis C virus, as well as daclatasvir , elbasvir (for HCV1 and HCV4), ledipasvir , MK-8408 , odalasvir , ombitasvir , ravidasvir and velpatasvir . Samatasvir is given orally. The EC ₅₀ for samatasvir in vitro is between 2 and 24 pM for the HCV genotypes 1 to 5. the EC ₅₀ for the genotype HCV-1b increases ten-fold in the presence of 40% volume fraction of serum . A phase II clinical study was published in 2014.

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ ^a ^b J. P. Bilello, LB Lallos, JF McCarville, M. La Colla, I. Serra, C. Chapron, JM Gillum, C. Pierra, DN Standring, M. Seifer: In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. In: Antimicrobial agents and chemotherapy. Volume 58, number 8, August 2014, pp. 4431-4442, doi: 10.1128 / AAC.02777-13 , PMID 24867983 , PMC 4136001 (free full text).
↑ B. Vince, JM Hill, EJ Lawitz, W. O'Riordan, LR Webster, DM Gruener, RS Mofsen, A. Murillo, E. Donovan, J. Chen, JF McCarville, JZ Sullivan-Bólyai, D. Mayers, XJ Zhou: A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. In: Journal of hepatology. Volume 60, number 5, May 2014, pp. 920-927, doi: 10.1016 / j.jhep.2014.01.003 , PMID 24434503 .

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[Bilello-2] J. P. Bilello, LB Lallos, JF McCarville, M. La Colla, I. Serra, C. Chapron, JM Gillum, C. Pierra, DN Standring, M. Seifer: In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. In: Antimicrobial agents and chemotherapy. Volume 58, number 8, August 2014, pp. 4431-4442, doi: 10.1128 / AAC.02777-13 , PMID 24867983 , PMC 4136001 (free full text).

[3] B. Vince, JM Hill, EJ Lawitz, W. O'Riordan, LR Webster, DM Gruener, RS Mofsen, A. Murillo, E. Donovan, J. Chen, JF McCarville, JZ Sullivan-Bólyai, D. Mayers, XJ Zhou: A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. In: Journal of hepatology. Volume 60, number 5, May 2014, pp. 920-927, doi: 10.1016 / j.jhep.2014.01.003 , PMID 24434503 .